SI2869836T1 - DNA cepivo za uporabo pri pacientih z rakom trebušne slinavke - Google Patents

DNA cepivo za uporabo pri pacientih z rakom trebušne slinavke

Info

Publication number
SI2869836T1
SI2869836T1 SI201331605T SI201331605T SI2869836T1 SI 2869836 T1 SI2869836 T1 SI 2869836T1 SI 201331605 T SI201331605 T SI 201331605T SI 201331605 T SI201331605 T SI 201331605T SI 2869836 T1 SI2869836 T1 SI 2869836T1
Authority
SI
Slovenia
Prior art keywords
pancreatic cancer
cancer patients
dna vaccine
vaccine
dna
Prior art date
Application number
SI201331605T
Other languages
English (en)
Inventor
Heinz Lubenau
Original Assignee
Vaximm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaximm Ag filed Critical Vaximm Ag
Publication of SI2869836T1 publication Critical patent/SI2869836T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103Receptors for growth factors
    • A61K39/001109Vascular endothelial growth factor receptors [VEGFR]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0275Salmonella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • C12N1/205Bacterial isolates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36Adaptation or attenuation of cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/542Mucosal route oral/gastrointestinal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/80Vaccine for a specifically defined cancer
    • A61K2039/852Pancreas
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/42Salmonella
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201331605T 2012-07-05 2013-06-26 DNA cepivo za uporabo pri pacientih z rakom trebušne slinavke SI2869836T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12004995 2012-07-05
PCT/EP2013/001882 WO2014005683A1 (en) 2012-07-05 2013-06-26 Dna vaccine for use in pancreatic cancer patients
EP13732833.2A EP2869836B1 (en) 2012-07-05 2013-06-26 Dna vaccine for use in pancreatic cancer patients

Publications (1)

Publication Number Publication Date
SI2869836T1 true SI2869836T1 (sl) 2020-01-31

Family

ID=48741047

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201331605T SI2869836T1 (sl) 2012-07-05 2013-06-26 DNA cepivo za uporabo pri pacientih z rakom trebušne slinavke

Country Status (20)

Country Link
US (3) US9415098B2 (sl)
EP (2) EP2869836B1 (sl)
JP (1) JP6325534B2 (sl)
KR (1) KR102090612B1 (sl)
CN (1) CN104519908B (sl)
AU (2) AU2013286335B2 (sl)
BR (1) BR112014033046A2 (sl)
CA (1) CA2877938A1 (sl)
DK (1) DK2869836T3 (sl)
ES (1) ES2752141T3 (sl)
HU (1) HUE046138T2 (sl)
IL (1) IL236049B (sl)
LT (1) LT2869836T (sl)
MX (1) MX359315B (sl)
PL (1) PL2869836T3 (sl)
RU (1) RU2636348C2 (sl)
SG (1) SG11201500054QA (sl)
SI (1) SI2869836T1 (sl)
WO (1) WO2014005683A1 (sl)
ZA (1) ZA201409156B (sl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2752141T3 (es) * 2012-07-05 2020-04-03 Vaximm Ag Vacuna de ADN para uso en pacientes con cáncer de páncreas
CA2989247C (en) * 2015-06-18 2023-10-17 Vaximm Ag Vegfr-2 targeting dna vaccine for combination therapy
US20180153976A1 (en) 2015-06-18 2018-06-07 Vaximm Ag Novel cmv pp65 targeting dna vaccine for cancer immunotherapy
MX2019000415A (es) * 2016-07-13 2019-03-28 Vaximm Ag Procedimiento para la produccion de una vacuna de adn para inmunoterapia del cancer.
EP3524573B1 (en) 2016-10-07 2022-05-04 Denka Company Limited Boron nitride aggregated grain, method for producing same, and thermally conductive resin composition using same
CN109790026B (zh) 2016-10-21 2023-03-28 电化株式会社 球状氮化硼微粉、其制造方法及使用了其的导热树脂组合物
MX2019005212A (es) * 2016-11-04 2019-06-20 Vaximm Ag Vacuna de adn dirigida a wt1 para terapia de combinacion.
CN110291187A (zh) 2017-02-17 2019-09-27 万科斯蒙股份有限公司 新型的靶向vegfr-2的免疫治疗方法
CN110430893A (zh) 2017-03-17 2019-11-08 万科斯蒙股份有限公司 用于癌症免疫疗法的新型的靶向pd-l1的dna疫苗
JP7097438B2 (ja) 2017-07-11 2022-07-07 アクティム・セラピューティクス・インコーポレイテッド 遺伝子操作された免疫刺激性細菌菌株およびその使用
EP3820992A2 (en) 2018-07-11 2021-05-19 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
EP3846844A1 (en) * 2018-09-05 2021-07-14 Vaximm AG Neoantigen targeting dna vaccine for combination therapy
AU2021208400A1 (en) 2020-01-13 2022-08-11 Vaximm Ag Salmonella-based DNA vaccines in combination with an antibiotic
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
WO2022152939A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
WO2023105076A1 (en) * 2021-12-09 2023-06-15 Prokarium Limited Combination cancer therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR930001382B1 (ko) 1990-09-05 1993-02-27 보령신약 주식회사 경구용 장티프스 생균백신 및 그의 제조방법
US7094410B2 (en) 2002-03-02 2006-08-22 The Scripps Research Institute DNA vaccine against proliferating endothelial cells and methods of use thereof
ME00425B (me) 2003-05-30 2011-10-10 Genentech Inc Liječenje sa anti-vegf antitijelima
WO2013091898A1 (en) * 2011-12-22 2013-06-27 Vaximm Ag Method for producing high yield attenuated salmonella strains
ES2752141T3 (es) * 2012-07-05 2020-04-03 Vaximm Ag Vacuna de ADN para uso en pacientes con cáncer de páncreas

Also Published As

Publication number Publication date
MX359315B (es) 2018-09-25
EP3603664A1 (en) 2020-02-05
HUE046138T2 (hu) 2020-02-28
AU2017258877A1 (en) 2017-11-30
AU2013286335A1 (en) 2015-01-29
CN104519908A (zh) 2015-04-15
PL2869836T3 (pl) 2020-03-31
SG11201500054QA (en) 2015-03-30
IL236049B (en) 2020-04-30
US10293037B2 (en) 2019-05-21
KR102090612B1 (ko) 2020-03-19
EP2869836A1 (en) 2015-05-13
US20160250311A1 (en) 2016-09-01
WO2014005683A8 (en) 2014-04-03
US20190008936A1 (en) 2019-01-10
ZA201409156B (en) 2016-07-27
AU2017258877B2 (en) 2018-11-29
LT2869836T (lt) 2019-11-11
JP6325534B2 (ja) 2018-05-16
CN104519908B (zh) 2020-10-30
KR20150036361A (ko) 2015-04-07
CA2877938A1 (en) 2014-01-09
RU2636348C2 (ru) 2017-11-22
US20150165011A1 (en) 2015-06-18
IL236049A0 (en) 2015-01-29
WO2014005683A1 (en) 2014-01-09
DK2869836T3 (da) 2019-11-25
EP2869836B1 (en) 2019-09-25
AU2013286335B2 (en) 2017-08-10
ES2752141T3 (es) 2020-04-03
BR112014033046A2 (pt) 2017-06-27
JP2015522263A (ja) 2015-08-06
RU2015103758A (ru) 2016-08-27
MX2014015977A (es) 2015-03-20
US9415098B2 (en) 2016-08-16

Similar Documents

Publication Publication Date Title
ZA201409156B (en) Dna vaccine for use in pancreatic cancer patients
IL267242B (en) Cancer treatment
HK1192758A1 (zh) '- 用於治療癌症的 -氟- '-脱氧尿苷的氨基磷酸酯衍生物
EP2714073A4 (en) ANTI-CANCER ANTIGEN GENE VACCINE IN SITU
EP2897566A4 (en) MOTORIZED SUPPORT APPARATUS FOR PATIENT
EP2819629A4 (en) PATIENTS LIEGE
EP2752198A4 (en) PREPARATION OF VACCINE FOR THE TREATMENT OF CANCER
EP2815361A4 (en) DISPOSABLE PAYMENT CARDS
EP2892490A4 (en) PATIENT SUPPORT
SG11201500396TA (en) Tumor vaccination
PL2780332T3 (pl) Morfolinylobenzotriazyny do zastosowania w terapii rakowej
HK1205698A1 (en) Chondroitin for use in medicine
IL238453A0 (en) Trans-clomiphene for use in cancer treatment
EP2925332A4 (en) PLACENTAL IMP THERAPY AGAINST CANCER
HK1210023A1 (en) Cancer treatment
EP2934500A4 (en) COMBINATION THERAPY AGAINST CANCER
IL231564A0 (en) Treatment by vaccination
GB201218084D0 (en) Novel compounds and methods for use in medicine
GB201222563D0 (en) Cancer treatment
IL239231A0 (en) Combined cancer treatment
GB201107549D0 (en) Cancer vaccine
GB201201728D0 (en) Improvements in or relating to patient support